Des Moines Register
Thousands of Iowans potentially escaped being hospitalized with COVID-19, or worse, after being treated by experimental monoclonal antibodies.
The treatment arrived in Iowa in mid-November, shortly after it received emergency approval by federal regulators, and it has shown promising results in keeping Iowans sick with COVID-19 from the direst of outcomes.
The treatment isn’t for everyone who tests positive for the coronavirus. It is generally reserved for people with a higher risk of hospitalization or more dire outcomes from the virus.
And while its first deployment came during a spike of COVID-19 illnesses in Iowa, and preceded the decline in cases, it’s not as simple as cause and effect, MercyOne Dr. Casey Rice said.
Des Moines Register
Thousands of Iowans potentially escaped being hospitalized with COVID-19, or worse, after being treated by experimental monoclonal antibodies.
The treatment arrived in Iowa in mid-November, shortly after it received emergency approval by federal regulators, and it has shown promising results in keeping Iowans sick with COVID-19 from the direst of outcomes.
The treatment isn’t for everyone who tests positive for the coronavirus. It is generally reserved for people with a higher risk of hospitalization or more dire outcomes from the virus.
And while its first deployment came during a spike of COVID-19 illnesses in Iowa, and preceded the decline in cases, it’s not as simple as cause and effect, MercyOne Dr. Casey Rice said.